Microbiological findings and treatment of EBV-associated hemophagocytic lymphohistiocytosis: A case report

Archivum Immunologiae et Therapiae Experimentalis

Volumn 58, Issue 3, 2010, Pages 247-252

  Przybylski, Maciej ^a,b   Dzieciątkowski, Tomasz ^a,b   Zduńczyk, Dorota ^a   Jędrzejczak, Wiesław Wiktor ^a   Łuczak, Mirosław ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Public Independent Central Clinical Hospital in Warsaw   (Poland)

Author keywords

Epstein barr virus; Hemophagocytic lymphohistiocytosis; Real time PCR

Indexed keywords

ACICLOVIR; CYCLOSPORIN; DEXAMETHASONE; ETOPOSIDE; IMMUNOGLOBULIN; METHISOPRINOL; STEROID; VIRUS DNA;

ADOLESCENT; ARTICLE; CASE REPORT; ELECTRON MICROSCOPY; EPISTAXIS; EPSTEIN BARR VIRUS; ERYTHROCYTE TRANSFUSION; FEVER; GINGIVA BLEEDING; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEPATOSPLENOMEGALY; HUMAN; HUMAN TISSUE; HYPOPROTEINEMIA; INFECTIOUS MONONUCLEOSIS; JAUNDICE; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHADENOPATHY; MACULOPAPULAR RASH; MALE; PLASMAPHERESIS; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN ULCER; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TONSILLITIS; VIRUS DETECTION; VIRUS LIKE AGENT;

EID: 77953021774     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-010-0071-4     Document Type: Article

References (14)

1. Chuang HC, Lay JD, Hsieh WC et al (2007) Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus associated T-cell lymphoma: nuclear factor-kappaB pathway as a potential therapeutic target. Cancer Sci 98:1281-1287.
2. Fisman DN (2000) Hemophagocytic syndromes and infection. Emerg Infect Dis 6:601-608.
3. Henter JI, Tondini C, Pritchard J (2004) Histiocyte disorders. Crit Rev Oncol Hematol 50:157-174.
4. Imashuku S (2002) Clinical features and treatment strategies of Epstein-Barr virus associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 44:259-272. (Pubitemid 35435291)
5. Imashuku S, Kuriyama K, Teramura T et al (2001) Requirement for etoposide in the treatment of Epstein-Barr virus associated hemophagocytic lymphohistiocytosis. J Clin Oncol 19:2665-2673.
6. Imashuku S, Teramura T, Tauchi H et al (2004) Longitudinal followup of patients with Epstein-Barr virus associated hemophagocytic lymphohistiocytosis. Haematologica 89:183-188.
7. Iwatsuki K, Xu Z, Ohtsuka M et al (2000) Cutaneous lymphoproliferative disorders associated with Epstein-Barr virus infection: a clinical overview. J Dermatol Sci 22:181-195.
8. Janka GE (2007) Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 166:95-109.
9. Jenson HB (2000) Acute complications of Epstein-Barr virus infectious mononucleosis. Curr Opin Pediatr 12:263-268.
10. Kasahara Y, Yachie A (2002) Cell type specific infection of Epstein- Barr virus (EBV) in EBV associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol Hematol 44:283-294.
11. Okano M (2000) Haematological associations of Epstein-Barr virus infection. Baillieres Best Pract Res Clin Haematol 13:199-214.
12. Sullivan JL, Woda BA, Herrod HG et al (1985) Epstein-Barr virus associated hemophagocytic syndrome: virological and immunopathological studies. Blood 65:1097-1104.
13. Tiab M, Mechinaud F, Harousseau JL (2000) Haemophagocytic syndrome associated with infections. Baillieres Best Pract Res Clin Haematol 13:163-178.
14. Verbsky JW, Grossman WJ (2006) Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann Med 38:20-31.